Thymic Stromal Lymphopoietin Attenuates the Development of Atherosclerosis in ApoE ^−/− Mice

Abstract

Background Thymic stromal lymphopoietin ( TSLP ) is a cytokine with multiple effects on the body. For one thing, TSLP induces Th2 immunoreaction and facilitates allergic reaction; for another, it promotes the differentiation of naturally occurring CD 4 + CD 25 + Foxp3 + regulatory T cells (nTregs) and maintains immune tolerance. However, the exact role of TSLP in atherosclerosis remains unknown. Methods and Results In vitro, we examined the phenotype of TSLP ‐conditioned bone marrow dendritic cells ( TSLP ‐ DC s) of apolipoprotein E–deficient (ApoE −/− ) mice and their capacity to induce the differentiation of Tregs. Our results indicated that TSLP ‐ DC s obtained the characteristics of tolerogenic dendritic cells and increased a generation of CD 4 + latency‐associated peptide ( LAP ) + Tregs and nTregs when cocultured with naive T cells. In addition, the functional relevance of TSLP and TSLP ‐ DC s in the development of atherosclerosis was also determined. Interestingly, we found that TSLP was almost absent in cardiovascular tissue of ApoE −/− mice, and TSLP administration increased the levels of antioxidized low‐density lipoprotein IgM and IgG 1 , but decreased the levels of IgG 2a in plasma. Furthermore, mice treated with TSLP and TSLP ‐ DC s developed significantly fewer (32.6% and 28.2%, respectively) atherosclerotic plaques in the aortic root compared with controls, along with increased numbers of CD 4 + LAP + Tregs and nTregs in the spleen and decreased inflammation in the aorta, which could be abrogated by anti‐ TGF ‐β antibody. Conclusions Our results revealed a protective role for TSLP in atherosclerosis that is possibly mediated by reestablishing a tolerogenic immune response, which may represent a novel possibility for treatment or prevention of atherosclerosis.